Email Alert | RSS

Journal of Peking University(Health Sciences) ›› 2019, Vol. 51 ›› Issue (1): 49-52. doi: 10.19723/j.issn.1671-167X.2019.01.009

Previous Articles     Next Articles

Study of surgery combined with 125I brachytherapy for adenoid cystic carcinoma of oral and maxillofacial region

Cong LI,Shu-ming LIU,Lei ZHENG,Ming-wei HUANG,Yan SHI,Xiao-ming LV,Jian-guo ZHANG,Jie ZHANG()   

  1. Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China
  • Received:2018-10-11 Online:2019-02-18 Published:2019-02-26
  • Contact: Jie ZHANG E-mail:zhangjie06@126.com

RICH HTML

 10   

PDF (PC)

365

Abstract:

Objective: To retrospectively analyze the results of treatment outcome by surgery combined with 125I brachytherapy and correlative factors of adenoid cystic carcinoma (ACC). Methods: In the study, 75 patients with primary ACC of oral and maxillofacial region were treated by surgery combined with 125I seeds brachytherapy. Radical resection or subtotal resection was applied for the tumor. The brachytherapy treatment planning system was used to create implant plans with the prescribed dose of 60 Gy to 120 Gy. The 125I seeds were implanted intraoperatively or postoperatively. The regular follow-up was required. The Kaplan-Meier method was used to assess the tumor control rate and the patients’ survival rates. Meanwhile, the Cox regression analysis was used to find out the prognostic factors. Results: Local control rates at the end of 3 and 5 years were as follows: T1-T2, 92.2% and 82.0%; T3-T4, 82.6% and 82.6%; and overall, 90.0% and 78.8%. The disease-free survival rates were 74.9% and 54.3%, respectively. The overall survival rates for all the patients were 86.0% and 79.6%, respectively at the end of 3 and 5 years and were 91.3% and 91.3% for T1-T2 patients vs. 73.9% and 59.7% for T3-T4 patients. Distant metastasis-free survival rates at the end of 3 and 5 years were 84.4% and 76.7%, respectively. The distant metastasis-free survival rates at the end of 3 and 5 years were 83.4% and 79.6% with T1-T2 lesion compared with 86.0% and 67.8% with T3-T4 lesion. According to the COX univariate analysis and multivariate analysis, the risk of local recurrence would be raised by the age. Tumor stage and tumor site were the prognostic factors of the overall survival rates. Conclusion: 125I brachytherapy conducted as an adjuvant therapy postoperatively of ACC of oral and maxillofacial region can acquire satisfactory local-regional control, distant metastasis-free survival, disease-free survival and overall survival. Tumors are prone to recur on the older patients. Patients having advanced tumor stage or tumor located in the nasal cavity or sinuses will suffer lower survival rates.

Key words: Carcinoma, adenoid cystic, Mouth neoplasms, Brachytherapy, Iodine radioisotopes, Prognosis

CLC Number: 

  • R739.8

Table 1

Characteristics of 75 patients with ACC"

Items Data
Gender,n (%)
Male 21 (28)
Female 54 (72)
Age/years, median (range) 48.0 (18-74)
Follow-up time/months, median (range) 46.8 (0.4-111.0)
Tumor site,n (%)
Parotid glands 24 (32.0)
Submandibular glands 13 (17.3)
Sublingual glands 7 (9.3)
Palate 11 (14.7)
Mouth floor 11 (14.7)
Cheek 2 (2.7)
Tongue 3 (4.0)
Parapharyngeal 1 (1.3)
Other 3 (4.0)
T stage,n (%)
T1 22 (29.3)
T2 19 (25.3)
T3 2 (2.7)
T4 23 (30.7)
Not reported 9 (12.0)
N stage,n (%)
N0 64 (85.3)
N1 3 (4.0)
Not reported 8 (10.7)
Surgical margins,n (%)
Positive 14 (18.7)
Clear 61(81.3)
[1] Kokemueller H, Eckardt A, Brachvogel P , et al. Adenoid cystic carcinoma of the head and neck: a 20 years experience[J]. Int J Oral Maxillofac Surg, 2004,33(1):25-31.
doi: 10.1054/ijom.2003.0448 pmid: 14690656
[2] Zhang CY, Xia RH, Han J , et al. Adenoid cystic carcinoma of the head and neck: clinicopathologic analysis of 218 cases in a Chinese population[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2013,115(3):368-375.
doi: 10.1016/j.oooo.2012.11.018 pmid: 23453028
[3] Tian Z, Li L, Wang L , et al. Salivary gland neoplasms in oral and maxillofacial regions: a 23-year retrospective study of 6 982 cases in an eastern Chinese population[J]. Int J Oral Maxillofac Surg, 2010,39(3):235-242.
doi: 10.1016/j.ijom.2009.10.016 pmid: 19951834
[4] 于世凤, 高岩 . 口腔组织学与病理学[M]. 北京: 北京大学医学出版社, 2005: 307.
[5] Maciejewski A, Szymczyk C, Wierzgon J . Outcome of surgery for adenoid cystic carcinoma of head and neck region[J]. J Craniomaxillofac Surg, 2002,30(1):59-61.
doi: 10.1054/jcms.2001.0265 pmid: 12064885
[6] Garden AS, Weber RS, Morrison WH , et al. The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation[J]. Int J Radiat Oncol Biol Phys, 1995,32(3):619-626.
doi: 10.1016/0360-3016(95)00122-F pmid: 7790247
[7] Mendenhall WM, Morris CG, Amdur RJ , et al. Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck[J]. Head Neck, 2004,26(2):154-162.
doi: 10.1002/hed.10380 pmid: 14762884
[8] Huang MW, Zheng L, Liu SM , et al. 125I brachytherapy alone for recurrent or locally advanced adenoid cystic carcinoma of the oral and maxillofacial region [J]. Strahlenther Onkol, 2013,189(6):502-507.
doi: 10.1007/s00066-013-0324-3
[9] Takagi M, Demizu Y, Hashimoto N , et al. Treatment outcomes of particle radiotherapy using protons or carbon ions as a single-modality therapy for adenoid cystic carcinoma of the head and neck[J]. Radiother Oncol, 2014,113(3):364-370.
doi: 10.1016/j.radonc.2014.11.031 pmid: 25467004
[10] Chen AM, Bucci MK, Weinberg V , et al. Adenoid cystic carcinoma of the head and neck treated by surgery with or without post-operative radiation therapy: prognostic features of recurrence[J]. Int J Radiat Oncol Biol Phys, 2006,66(1):152-159.
doi: 10.1016/j.ijrobp.2006.04.014 pmid: 16904520
[11] Al-Mamgani A, van Rooij P, Sewnaik A , et al. Adenoid cystic carcinoma of parotid gland treated with surgery and radiotherapy: long-term outcomes, QoL assessment and review of the literature[J]. Oral Oncol, 2012,48(3):278-283.
doi: 10.1016/j.oraloncology.2011.10.014 pmid: 22093375
[12] Jensen AD, Nikoghosyan AV, Poulakis M , et al. Combined intensity-modulated radiotherapy plus raster-scanned carbon ion boost for advanced adenoid cystic carcinoma of the head and neck results in superior locoregional control and overall survival[J]. Cancer, 2015,121(17):3001-3009.
doi: 10.1002/cncr.29443 pmid: 26043145
[13] Casler JD, Conley JJ . Surgical management of adenoid cystic carcinoma in the parotid gland[J]. Otolaryngol Head Neck Surg, 1992,106(4):332-338.
doi: 10.1177/019459989210600403 pmid: 1314372
[14] Iseli TA, Karnell LH, Preston TW , et al. Facial nerve sacrifice and radiotherapy in parotid adenoid cystic carcinoma[J]. Laryngoscope, 2008,118(10):1781-1786.
doi: 10.1097/MLG.0b013e31817fae29 pmid: 18758382
[15] Iseli TA, Karnell LH, Graham SM , et al. Role of radiotherapy in adenoid cystic carcinoma of the head and neck[J]. J Laryngol Otol, 2009,123(10):1137-1144.
doi: 10.1017/S0022215109990338 pmid: 19573256
[16] van Weert S, Bloemena E, van der Waal I , et al. Adenoid cystic carcinoma of the head and neck: a single-center analysis of 105 consecutive cases over a 30-year period[J]. Oral Oncol, 2013,49(8):824-829.
doi: 10.1016/j.oraloncology.2013.05.004 pmid: 23751614
[17] Zheng L, Zhang JG, Zhang J , et al. Preliminary results of 125I interstitial brachytherapy for locally recurrent parotid gland cancer in previously irradiated patients [J]. Head Neck, 2012,34(10):1445-1449.
doi: 10.1002/hed.21955
[18] Zheng L, Zhang JG, Song TL , et al. 125I seed implant brachythe-rapy for the treatment of parotid gland cancers in children and adolescents [J]. Strahlenther Onkol, 2013,189(5):401-406.
doi: 10.1007/s00066-013-0313-6 pmid: 23519359
[19] 郭华秋, 刘树铭, 张杰 , 等. 老年头颈癌患者 125I粒子植入治疗后的生存质量研究 [J]. 中华放射医学与防护杂志, 2013,33(5):501-504.
doi: 10.3760/cma.j.issn.0254-5098.2013.05.011
[20] Lloyd S, Yu JB, Wilson LD , et al. Determinants and patterns of survival in adenoid cystic carcinoma of the head and neck, including an analysis of adjuvant radiation therapy[J]. Am J Clin Oncol, 2011,34(1):76-81.
doi: 10.1097/COC.0b013e3181d26d45
[21] 农晓琳, 陈琦, 黎燕宁 , 等. 63例涎腺腺样囊性癌患者预后相关因素的Cox模型分析[J]. 口腔医学, 2011,31(1):1-4.
[1] ZHOU Chuan-xiang,ZHOU Zheng,ZHANG Ye,LIU Xiao-xiao,GAO Yan. Clinicopathological study in 28 cases of oral basaloid squamous cell carcinomas [J]. Journal of Peking University (Health Sciences), 2022, 54(1): 62-67.
[2] SU Jun-qi,SONG Yang,XIE Shang. Analysis of etiological characteristics and establishment of prediction model of postoperative infections in patients undergoing oral squamous cell carcinoma surgery with free flap reconstruction [J]. Journal of Peking University (Health Sciences), 2022, 54(1): 68-76.
[3] Fei WANG,Xiang ZHU,Bei HE,Hong ZHU,Ning SHEN. Spontaneous remission of follicular bronchiolitis with nonspecific interstitial pneumonia: A case report and literature review [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1196-1200.
[4] Wei-bo GAO,Mao-jing SHI,Hai-yan ZHANG,Chun-bo WU,Ji-hong ZHU. Relationship between marked hyperferritinemia and hemophagocytic lymphohistiocytosis [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 921-927.
[5] Mei-xiang ZHANG,Wen-zhi SHI,Jian-xin LIU,Chun-jian WANG,Yan LI,Wei WANG,Bin JIANG. Clinical characteristics and prognosis of MLL-AF6 positive patients with acute myeloid leukemia [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 915-920.
[6] Yu TIAN,Xiao-yue CHENG,Hui-ying HE,Guo-liang WANG,Lu-lin MA. Clinical and pathological features of renal cell carcinoma with urinary tract tumor thrombus: 6 cases report and literature review [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 928-932.
[7] Yan-fang JIANG,Jian WANG,Yong-jian WANG,Jia LIU,Yin PEI,Xiao-peng LIU,Ying-fang AO,Yong MA. Mid-to-long term clinical outcomes and predictors after anterior cruciate ligament revision [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 857-863.
[8] XIAO Ruo-tao,LIU Cheng,XU Chu-xiao,HE Wei,MA Lu-lin. Prognostic value of preoperative platelet parameters in locally advanced renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 647-652.
[9] PANG Yong,ZHANG Sha,YANG Hua,ZHOU Rou-li. Serum LAPTM4B-35 protein as a novel diagnostic marker for hepatocellular carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 710-715.
[10] YU Yan-fei,HE Shi-ming,WU Yu-cai,XIONG Sheng-wei,SHEN Qi,LI Yan-yan,YANG Feng,HE Qun,LI Xue-song. Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 640-646.
[11] SUN Zheng-hui,HUANG Xiao-juan,DONG Jing-han,LIU Zhuo,YAN Ye,LIU Cheng,MA Lu-lin. Risk factors of renal sinus invasion in clinical T1 renal cell carcinoma patients undergoing nephrectomy [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 659-664.
[12] ZHAO Xun,YAN Ye,HUANG Xiao-juan,DONG Jing-han,LIU Zhuo,ZHANG Hong-xian,LIU Cheng,MA Lu-lin. Influence of deep invasive tumor thrombus on the surgical treatment and prognosis of patients with non-metastatic renal cell carcinoma complicated with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 665-670.
[13] HAN Song-chen,HUANG Zi-xiong,LIU Hui-xin,XU Tao. Renal functional compensation after unilateral radical nephrectomy of renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 680-685.
[14] HONG Peng,TIAN Xiao-jun,ZHAO Xiao-yu,YANG Fei-long,LIU Zhuo,LU Min,ZHAO Lei,MA Lu-lin. Bilateral papillary renal cell carcinoma following kidney transplantation: A case report [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 811-813.
[15] CHEN Huai-an,LIU Shuo,LI Xiu-jun,WANG Zhe,ZHANG Chao,LI Feng-qi,MIAO Wen-long. Clinical value of inflammatory biomarkers in predicting prognosis of patients with ureteral urothelial carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 302-307.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] . [J]. Journal of Peking University(Health Sciences), 2009, 41(4): 456 -458 .
[2] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 125 -128 .
[3] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 135 -140 .
[4] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 158 -161 .
[5] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 217 -220 .
[6] . [J]. Journal of Peking University(Health Sciences), 2009, 41(1): 52 -55 .
[7] . [J]. Journal of Peking University(Health Sciences), 2009, 41(3): 297 -301 .
[8] . [J]. Journal of Peking University(Health Sciences), 2009, 41(5): 505 -515 .
[9] . [J]. Journal of Peking University(Health Sciences), 2009, 41(5): 599 -601 .
[10] . [J]. Journal of Peking University(Health Sciences), 2009, 41(5): 516 -520 .
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd